San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fennec Pharmaceuticals Inc. (NASDAQ: FENC). The investigation focuses on Fennec Pharmaceuticals executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased Fennec Pharmaceuticals securities?If you purchased Fennec Pharmaceuticals securities and suffered losses on your investment, join our investigation now: Click h ...

On the marketing front, Hackman said the company is expanding efforts to activate young adult testicular cancer patients and plans to launch an initiative tied to the Indy 500 in May in partnership with a testicular cancer advocacy group. He also said Fennec expects a significant presence at the ASCO meeting in Chicago later this year.Management said conversion rates improved over the course of the year, citing an increase from 50% in the first quarter to 70% in the fourth quarter. Hackman said these result ...

Fennec Pharmaceuticals (NasdaqCM:FENC) Q4 2025 Earnings call March 24, 2026 08:30 AM ET Company Participants Jeff Hackman - CEO Pierre S. Sayad - Chief Medical Officer Robert Andrade - CFO Conference Call Participants Chase Knickerbocker - Senior Research Analyst Madison El-Saadi - Healthcare Equity Research Analyst Raghuram Selvaraju - Managing Director and Equity Research Analyst None - Analyst None - Analyst Operator Good morning, ladies and gentlemen. Welcome to Fennec Pharmaceuticals' fourth quarter an ...

Fennec Pharmaceuticals (NasdaqCM:FENC) Q4 2025 Earnings call March 24, 2026 08:30 AM ET Company ParticipantsJeffrey S. Hackman - CEOPierre S. Sayad - CMORobert Andrade - CFOConference Call ParticipantsChase Knickerbocker - Senior Research AnalystMadison El-Saadi - Healthcare Equity Research AnalystRaghuram Selvaraju - Managing Director and Equity Research AnalystSudhanva Nathan - AnalystNone - AnalystOperatorGood morning, ladies and gentlemen. Welcome to Fennec Pharmaceuticals' fourth quarter and full year ...

Fennec Pharmaceuticals (NasdaqCM:FENC) Q4 2025 Earnings call March 24, 2026 08:30 AM ET Company ParticipantsAlex von Riesemann - AVP of Biotech Equity ResearchJeff Hackman - CEOPierre S. Sayad - Chief Medical OfficerRobert Andrade - CFOConference Call ParticipantsChase Knickerbocker - Senior Research AnalystMadison El-Saadi - Healthcare Equity Research AnalystRaghuram Selvaraju - Managing Director and Equity Research AnalystSudan Loganathan - Biotechnology Equity Research AnalystOperatorGood morning, ladies ...

Fennec Pharmaceuticals (NasdaqCM:FENC) Q4 2025 Earnings call March 24, 2026 08:30 AM ET Speaker3Good morning, ladies and gentlemen. Welcome to Fennec Pharmaceuticals' fourth quarter and full year 2025 earnings and corporate update conference call. At this time, all participants are on a listen-only mode. Later, we will conduct a question-and-answer session, and instructions on how to participate will be given at that time. As a reminder, today's conference call is being recorded. Now I'd like to send the co ...

~ Delivered Record Annual Revenue with Full-Year Net PEDMARK® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75% Growth Over Q4 2024 Net Product Sales ~ ~ Executed on 2025 Clinical Data Strategy to Expand Real-World Validation of PEDMARK® Across New Tumor Types and Patient Populations Through Independent, Institution-Led Research ~ ~ Achieved Record Performance with All-Time High Patient Enrollments and Conversion Rates i ...

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) will release earnings results for its fourth quarter, before the opening bell on Tuesday, March 24.Analysts expect the Research Triangle Park, North Carolina-based company to report quarterly earnings at 4 cents per share, versus a year-ago loss of 6 cents per share. The consensus estimate for Core & Main's quarterly revenue is $14.73 million, versus $7.92 million a year earlier, according to data from Benzinga Pro.On March 16, Fennec Pharmaceuticals announced a set ...

Core Insights - Fennec Pharmaceuticals Inc. will release its full year and fourth quarter 2025 financial results on March 24, 2026, before U.S. market opening [1] - A conference call and webcast will be held on the same day to discuss the financial and business results [1][2] Company Overview - Fennec Pharmaceuticals is focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy [3] - The company is commercializing PEDMARK, which aims to reduce the risk of platinum-induced ototoxicity, and has received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023 under the name PEDMARQSI [3] Licensing and Market Presence - In March 2024, Fennec entered an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI in Europe, U.K., Australia, and New Zealand [4] - PEDMARQSI is currently available in the U.K. and Germany [4] Regulatory Status and Protection - PEDMARK has received Orphan Drug Exclusivity in the U.S., and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing eight years plus two years of data and market protection [5] - Fennec holds patents for PEDMARK that extend protection until 2039 in both the U.S. and internationally [5]

Core Insights - Fennec Pharmaceuticals has reached a settlement with Cipla regarding the litigation over Cipla's application to market a generic version of PEDMARK, with Cipla agreeing not to enter the market until September 1, 2033, or earlier under specific conditions [1] Company Overview - Fennec Pharmaceuticals is a specialty pharmaceutical company focused on reducing ototoxicity in cancer patients undergoing cisplatin-based chemotherapy [14] - PEDMARK is the first FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients aged 1 month and older with localized, non-metastatic solid tumors [2][6] Product Details - PEDMARK is a unique formulation of sodium thiosulfate available in single-dose, ready-to-use vials for intravenous use [2] - The product has been endorsed by the National Comprehensive Cancer Network (NCCN) for the adolescent and young adult population with a 2A recommendation [3] Market Context - Approximately 500,000 patients in the U.S. are diagnosed annually with cancers treatable by platinum-based chemotherapy, with many experiencing lifelong hearing loss due to ototoxicity [4] - Prior to PEDMARK's FDA approval, there were no preventative agents for hearing loss resulting from cancer treatment, significantly impacting patients' quality of life [4] Clinical Studies - PEDMARK has been validated through two Phase 3 clinical studies, COG ACCL0431 and SIOPEL 6, demonstrating its efficacy in reducing ototoxicity [5] - The COG ACCL0431 study included various childhood cancers treated with intensive cisplatin therapy, while SIOPEL 6 focused on hepatoblastoma patients [5] Regulatory and Commercialization Status - PEDMARK received FDA approval in September 2022 and has also been approved in Europe and the U.K. under the brand name PEDMARQSI [14][15] - Fennec has entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of PEDMARQSI in Europe, the U.K., Australia, and New Zealand [15] - The product has Orphan Drug Exclusivity in the U.S. and Pediatric Use Marketing Authorization in Europe, providing significant market protection [16]